Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GDC 4198

Next Previous
Drug Profile

GDC 4198

Alternative Names: GDC-4198; RG 6794; RGT-419B

Latest Information Update: 14 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Regor Therapeutics
  • Developer Genentech; Regor Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Cyclin-dependent kinase 2 inhibitors; Cyclin-dependent kinase 4 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II HER2 negative breast cancer
  • Phase I Solid tumours

Most Recent Events

  • 22 Apr 2026 Pharmacodynamic data from preclinical trial in Breast cancer presented at 117th Annual Meeting of the American Association for Cancer Research (AACR-2026)
  • 09 Dec 2025 Efficacy and adverse events data from a phase-I clinical trials in HER2-negative breast cancer presented at the 48th Annual San Antonio Breast Cancer Symposium(SABCS-2025)
  • 09 Dec 2025 Pharmacodynamics data from a preclinical trial in HER2-positive breast cancer presented at the 48th Annual San Antonio Breast Cancer Symposium (SABCS-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top